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KEY POINTS
• Question: Can dezocine, a nonaddictive opioid, be used to alleviate opioid dependence and
study-related mechanisms?
• Findings: Dezocine significantly reduced morphine withdrawal syndrome in a morphine-depen-
dent rat model comparable to that of buprenorphine; similarities and differences in molecular
targets between dezocine and buprenorphine were identified.
• Meaning: Dezocine could potentially be used to manage opioid dependence; its unique
molecular targets provide a valuable tool for studying mechanisms of opioid dependence and
developing novel therapeutics.
BACKGROUND: Opioid dependence is a major public health issue without optimal therapeutics. 
This study investigates the potential therapeutic effect of dezocine, a nonaddictive opioid, in 
opioid dependence in rat models.
METHODS: Dezocine was administered intraperitoneally to a morphine-dependent rat model to 
investigate its effect on withdrawal and conditioned place preference (CPP). Effect of dezocine on 
morphine withdrawal syndrome and CPP was analyzed using 2-way analysis of variance (ANOVA) 
followed by Tukey’s post hoc test. Buprenorphine and vehicle solution containing 20% (v/v) 
dimethyl sulfoxide were used for positive and negative control, respectively. The astrocytes activa-
tion in nucleus accumbens was assessed by immunofluorescence assay of glial fibrillary acidic 
protein. Effect of dezocine and buprenorphine on the internalization of κ opioid receptor (KOR) was 
investigated using Neuro2A expressing KOR fused to red fluorescent protein tdTomato (KOR-tdT). 
Buprenorphine and dezocine were screened against 44 G-protein–coupled receptors, ion chan-
nels, and transporter proteins using radioligand-binding assay to compare the molecular targets.
RESULTS: The mean withdrawal score was reduced in rats treated with 1.25 mg·kg−1 dezocine 
compared to vehicle-treated control animals starting from the day 1 (mean difference: 7.8; 95% 
confidence interval [CI], 6.35–9.25; P < .0001 by 2-way ANOVA). Significance was observed 
at all treatment days, including day 7 (mean difference: 2.13; 95% CI, 0.68–3.58; P < .001 
by 2-way ANOVA). Furthermore, dezocine inhibited the reinstatement of morphine-induced CPP 
(mean difference: 314; 95% CI, 197.9–430.1; P < .0001 by 2-way ANOVA) compared to the 
control group. Chronic morphine administration induced astrocytes activation in nucleus accum-
bens, which was attenuated by dezocine. Dezocine blocked the agonist-induced KOR internal-
ization in vitro, 1 of the mechanisms involved in the downstream signaling and development 
of opioid dependence. Dezocine had affinity to norepinephrine and serotonin transporters and 
sigma-1 receptor, whereas buprenorphine showed no activity against these targets.
CONCLUSIONS: Dezocine could potentially be used to alleviate opioid dependence. Due to 
the unique molecular target profile different from buprenorphine, it might have important 
value in studying the mechanisms of morphine dependence and developing novel therapeutic 
approaches.  (Anesth Analg 2019;128:1328–35)
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Opioid dependence, a growing clinical and social problem, is characterized by tolerance, with-drawal, and relapse, yet its precise management 
remains challenging. Increasing evidence indicates that 
κ opioid receptor (KOR) plays an important role in the 
development of µ opioid receptor (MOR)–mediated opi-
oid dependence, tolerance, and withdrawal.1–3 Activation 
of KOR relates to the opioid withdrawal, as morphine-
dependent KOR knockout mice displayed fewer with-
drawal symptoms than wild-type mice.4 Importantly, KOR 
undergoes qualitative and quantitative changes including 
elevated levels of mRNA in nucleus accumbens (NAcc), 
ventral tegmental area, and locus coeruleus—the brain 
regions associated with drug dependence,5–8 as well as ago-
nist-induced activation and internalization of the receptor 
for signal transduction cascades.9,10 Although accumulat-
ing evidence suggests that KOR agonists attenuate drug 
reward and demonstrate potent analgesic effects, these 
agonists have also been shown to accelerate drug relapse,11 
establish conditioned place aversions,12,13 and generate 
aversive mood, such as dysphoria14,15 and depression-like 
behaviors.16 Moreover, stimulation of KORs with selec-
tive agonists can result in a dynorphin–KOR–dependent 
reinstatement of extinguished cocaine-conditioned place 
preference (CPP) or self-administration.17 Considering that 
dynorphin–KOR system activation is likely to play a piv-
otal role in withdrawal, selective KOR antagonism may be 
a powerful therapeutic strategy for the treatment of opioid 
dependence.
Pharmacological replacement therapy with buprenor-
phine, a partial MOR agonist/KOR antagonist18 or in com-
bination with naltrexone or naloxone,19 has demonstrated 
advantages over a full µ agonist methadone in individuals 
with opioid dependence. However, buprenorphine has high 
affinity to µ receptors, it can cause mild to moderate depen-
dence, and it precipitated withdrawal effects, along with 
the evident buprenorphine-induced hepatitis. Thus, novel 
medication for opioid dependence is needed.
Different from buprenorphine, dezocine, a mixed partial 
MOR agonist and KOR antagonist, is not categorized as a 
controlled substance and has been used for postoperative 
analgesia for more than a decade. We recently demonstrated 
that dezocine is also an inhibitor of the norepinephrine 
(NET) and serotonin transporters (SERT) and sigma-120 
receptor, all of which are associated with pain21,22 and addic-
tion.23 Such a unique multitarget pharmacological profile of 
dezocine indicates that it might have the potential to man-
age opioid dependence. In this study, we tested the hypoth-
esis that dezocine could be an alternative medication for the 
management of opioid dependence using rat models.
METHODS
Materials
Pharmaceutical grade dezocine was obtained from Yangtze 
River Pharmaceutical Group (Jiangsu, China). Morphine 
sulfate, buprenorphine hydrochloride, and naloxone hydro-
chloride were obtained from the pharmacy of the University 
of Pennsylvania. For animal experiments, dezocine and 
buprenorphine were dissolved in 20% (v/v) dimethyl sulf-
oxide (DMSO) solution. The rest of the chemicals used were 
obtained from Sigma (St Louis, MO).
Animals
Animal experimental protocols were approved by 
the Institutional Animal Care and Use Committee at 
the University of Pennsylvania. Ten-week-old male 
Sprague‒Dawley rats weighing 200–250 g each were housed 
individually on a12/12-hour light/dark cycle in pathogen-
free conditions with food and water available ad libitum. 
The cage and room conditions and the health condition of 
the animals were monitored regularly.
Experiment 1: Dezocine on Withdrawal in 
Morphine-Induced Dependence
The morphine-dependent rat model was established by 
subcutaneous administration of ascending doses (5, 10, 20, 
40, 50, and 60 mg·kg−1) of morphine 3 times per day for 6 
consecutive days in all animals except those in the naïve 
group.24 Normal saline solution was injected subcutane-
ously into the naive control group. After the establishment 
of the model, rats were divided randomly into 4 groups 
(n = 15 per group). After the last dosage of morphine, the 
solution of normal saline (naive group), 20% (v/v) DMSO 
(vehicle control), dezocine 1.25 mg·kg−1 (dezocine group), 
and buprenorphine 0.3 mg·kg−1 (buprenorphine group, 
positive control) were injected intraperitoneally (i.p.). 
Intraperitoneal naloxone 2 mg·kg−1 injection was used to 
induce withdrawal syndrome. Injection volumes were 
kept constant (0.5 mL) in all experiments. The withdrawal 
syndrome was assessed within 30 minutes after naloxone 
injection. The mean withdrawal symptom scores were 
determined as described previously.25,26 The scores for wet 
dog shakes, writhing, teeth chattering, jumping, rearing, 
and body grooming were assigned as 1 (1–3 times), 2 (4–6 
times), and 3 (≥7 times); the scores for ptosis were assigned 
as 1 (1–4 times), 2 (5–8 times), and 3 (≥9 times).
Experiment 2: Assessment of Withdrawal With 
Various Doses of Dezocine
To evaluate the effect of administration (on days 1 and 7) 
of various doses of dezocine and buprenorphine in opioid 
withdrawal syndrome, the rat model was injected either 
dezocine (vehicle, 0.18, 0.37, 0.625, 1.25, 2.5 and 5 mg·kg−1, 
i.p.; n = 10 per group) or buprenorphine (vehicle, 0.1, 0.3,
and 1 mg·kg−1, i.p.; n = 10 per group). Normal saline was
administered to the naive group. Naloxone 2 mg·kg−1 injec-
tion was used to induce withdrawal syndrome as described
in experiment 1. The scores of morphine withdrawal syn-
drome were assessed as described above on days 1 and 7
and were plotted as a function of drug concentration.
CPP Experiment
CPP was used to test the reinstatement as described previ-
ously.27 The CPP apparatus (JL Behv-CPPG, Shanghai Jiliang 
Software Technology Co Ltd, Shanghai, China) consisted of 
2 compartments of equal size (15 × 15 × 37 cm3) with a 5 × 
7 cm2 door in the center. The 2 compartments had differ-
ent colors (black or white) and floor textures (mesh or grid). 
The time spent on each side and the number of crossings 
between the compartments were recorded by video and ana-
lyzed by DigBehv-CPP Video Analysis System (Shanghai 
Jiliang Software Technology Co Ltd).28 CPP was established 
as follows: before morphine administration (pretest), rats 
were allowed to move between 2 compartments (1 white 
and 1 black) freely for 15 minutes to determine the baseline 
preferences. For the conditioning training, rats were treated 
once a day for 4 consecutive days with 2 cycles of i.p. injec-
tions of morphine in the white compartment and then saline 
in the black compartment. After injection, rats were imme-
diately confined for 30 minutes to either the white or black 
compartment. Rats that received morphine injections were 
confined in the white compartment, while rats that received 
normal saline were in the black compartment. To test CPP 
scores, the door separating the black and white compart-
ments was left open, and rats were allowed to freely access 
both compartments for 15 minutes after ceasing injection. 
The time that the animal spent in the white compartment 
was considered as scores of CPP.29 The extinction training 
was similar to the conditioning training but not reinforced 
with morphine.30 All rats received a saline injection in both 
compartments, training for 30 minutes with the center door 
closed after injection. Extinction was confirmed after the 
scores of CPP returned to the baseline. Morphine 2 mg·kg−1 
was administered for reinstatement of CPP after the extinc-
tion training. The same volumes of normal saline were 
given as a negative control. The rats were then tested for the 
scores of CPP for 15 minutes.
Rats of CPP were randomly assigned to 3 groups using 
computerized random numbers generated by GraphPad 
software (10 rats in each group): DMSO group (morphine 
2 mg·kg−1 + 20% [v/v] DMSO), dezocine group (morphine 
2 mg·kg−1 + dezocine 1.25 mg·kg−1), and buprenorphine 
group (morphine 2 mg·kg−1 + buprenorphine 0.3 mg·kg−1). A 
naive group was used as negative control (no drug admin-
istration). After the extinction, dezocine and buprenorphine 
were administered i.p. 3 times a day for 4 consecutive days. 
In the DMSO group, the same volumes of 20% (v/v) DMSO 
were given as control. We picked a dose of dezocine (1.25 
mg·kg−1) that is about 4-fold of a dose of buprenorphine 
because the affinity of dezocine is 4-fold weaker than that of 
buprenorphine, and it is known to our group that this dose 
has positive pharmacological (analgesia) effects.
Immunofluorescence Assay for Determination of 
Astrocytes Activation
The astrocytes activation was assessed by immunofluorescence 
assay of the glial fibrillary acidic protein (GFAP), a major com-
ponent of the cytoskeleton of astrocytes. Animals from each 
group (n = 6) were euthanized with CO2 on day 3 of medica-
tion administration. The brain tissues were collected and fixed. 
Transverse brain sections were obtained and processed as 
described previously for immunofluorescence assay.31 Sections 
were incubated in 0.3% Triton X-100 containing 2% goat serum 
over 1 hour at room temperature and then over 48 hours at 4°C 
with anti-GFAP antibody (1:250; Santa Cruz Biotechnology, 
Inc, Santa Cruz, CA), followed by incubation for 1 hour with 
Alexa 488-conjugated secondary antibody (1:300; Santa Cruz 
Biotechnology, Inc) at room temperature. Tissue sections 
were imaged for green fluorescence by Olympus microscope 
(Olympus Co, Tokyo, Japan) and analyzed by pixel intensity 
profile u sing I mageJ 1 .48v s oftware ( National I nstitutes o f 
Health, Bethesda, MD). After subtracting the background sig-
nal, the ratio of mean pixel intensity (arbitrary units) of each 
group to naive group was calculated.
KOR Internalization Assay
This experiment is designed to determine whether dezocine 
and buprenorphine could block KOR activation as KOR 
antagonists. Neuro2A cells stably transfected with KOR-
tdT fusion protein were generated as described previously32 
and maintained in minimum essential media supplemented 
with 10% fetal bovine serum, 2% G418, 100 U·mL−1 penicillin, 
and 100 µg·mL−1 streptomycin in a humidified environment 
with 5% CO2 at 37°C. Cells were plated onto poly-d-lysine–
coated 8-well Lab-Tek chambered cover glasses. Forty-eight 
hours later, cells were stimulated with salvinorin A (10 
µM) for 30 minutes and imaged under an Olympus IX70 
microscope (Olympus, Melville, NY). To study the effect of 
dezocine or buprenorphine on salvinorin A–induced KOR 
trafficking, dezocine or buprenorphine (0.1, 1, or 10 µM final 
concentration) were added to the culture medium 30 min-
utes before the salvinorin A treatment.
Radioligand-Binding Assay and Affinity 
Determination
Radioligand-binding assay was conducted to screen the 
binding of dezocine and buprenorphine on 44 available 
receptors, including G-protein–coupled receptors, trans-
porter proteins, and ion channels as described previously.20 
The secondary binding assay was conducted to determine 
the affinity for selected receptors when the inhibition was 
>50% in the primary binding assay. Affinities for the recep-
tors are expressed as pKi (−logKi).
Statistical Analysis
All data are shown as mean ± standard deviation unless 
otherwise indicated. For the in vivo studies of the effect of 
dezocine on morphine withdrawal syndrome (experiment 1), 
2-way analysis of variance (ANOVA) was used to analyze
the effects among the groups (DMSO, dezocine, buprenor-
phine, and naive) and time period, including the interaction
between group and time factors. For CPP experiment, effect
Figure 1. Dezocine alleviates morphine withdrawal syndrome com-
parable to that of buprenorphine. Data represented as mean ± stan-
dard deviation (n = 15 in each group). P < .0001 in both dezocine 
versus dimethyl sulfoxide (DMSO) and buprenorphine versus DMSO 
groups by 2-way analysis of variance with Tukey’s post hoc test.
of the drug was analyzed using 2-way ANOVA with factors 
conditioning (pretest, posttest, extinction, and reinstatement) 
and drug treatment and interaction of these 2 factors. For 
the studies of the effect of administration of dezocine and 
buprenorphine on withdrawal syndrome in experiment 2, 
individual dose effects were analyzed using 1-way ANOVA. 
The data from immunofluorescence experiments were ana-
lyzed for statistical significance using 1-way ANOVA. Post 
hoc analyses were performed after 1- and 2-way ANOVA 
using Tukey’s test. Statistical power and sample size analyses 
were performed using G*Power 3.1.33 A sample size in each 
experiment was estimated based on our previous laboratory 
experience with this type of studies and indicated that 15 ani-
mals per group (10 in the case of the CPP experiment) would 
give a power from 0.8 to 0.9 at an α level of .05 for detecting a 
group difference of at least 5 and 200 units on withdrawal and 
CPP scale, respectively. For the studies of withdrawal syn-
drome, the assumed standard deviations were 3.7 and 2.9 in 
the drug-treated and control groups, respectively, to detect an 
effect size of 1.5, while they were 140 and 52 for CPP to detect 
an effect size of 1.9. According to the results of G*Power 3.1, 
the sample size in each group for withdrawal and CPP exper-
iments should be >12 and 7, respectively. Therefore, based 
on the sample size justification and our preliminary studies, 
we chose a sample size of 15 in withdrawal and 10 in CPP 
studies. Statistical analyses were performed with GraphPad 
Prism version 7 (GraphPad Software, Inc).
RESULTS
Dezocine Alleviates the Morphine Withdrawal 
Syndrome Comparable to That of Buprenorphine
After administration of naloxone 2 mg·kg−1, the morphine-
dependent group that received vehicle solution of DMSO 
(20% v/v) demonstrated significantly higher scores of with-
drawal symptoms on day 1 compared to that in the naive 
group (mean difference: 12.6; 95% confidence interval [CI], 
11.15–14.05; P < .0001 by 2-way ANOVA). Treatment with 
dezocine significantly reduced withdrawal scores starting 
from the first day compared to the vehicle control group 
(mean difference: 7.8; 95% CI, 6.35–9.25; P < .0001 by 2-way 
ANOVA). Significance was observed on all treatment days, 
including day 7 (mean difference: 2.13; 95% CI, 0.68–3.58; P 
< .001 by 2-way ANOVA; Figure 1). Significant decrease of 
withdrawal score was also present in the control buprenor-
phine group from the first day of administration compared 
to the vehicle group (mean difference: 6.8; 95% CI, 5.35–8.25; 
P < .0001 by 2-way ANOVA). The 2-way ANOVA of these 
data revealed significant effects for group (F0.05,3,392 = 331.9; 
P < .0001) and time period (F0.05,6,392 = 54.3; P < .0001), as 
well as statistically significant group and time interaction 
(F0.05,18,392 = 11.24; P < .0001). Results indicated that dezocine 
alleviated the morphine withdrawal syndrome in mor-
phine-dependent rats.
Dezocine Alleviates Morphine Withdrawal 
Syndrome With Various Doses
To assess the effects of i.p. injection of dezocine on pre-
cipitated withdrawal behavior, morphine-dependent rats 
were injected with various doses of dezocine ranging from 
0.18 to 5 mg·kg−1 10 minutes before the naloxone 2 mg kg−1 
injection on days 1 and 7 and were evaluated for 30 min-
utes. Naloxone administration induced significantly higher 
scores of withdrawal symptoms in the morphine-dependent 
group that received vehicle solution of DMSO (20% v/v) on 
day 1 (mean difference: 12.8; 95% CI, 10.2–15.4; P < .0001 by 
1-way ANOVA) and day 7 (mean difference: 2.3; 95% CI,
0.42–4.18; P < .01 by 1-way ANOVA) compared to that in
the naïve group. Administration of dezocine starting from
lower doses decreased mean withdrawal score on day 1
(0.37 mg·kg−1: mean difference: −5.4; 95% CI, −7.68 to −3.12;
P < .0001; 0.625 mg·kg−1: mean difference: −6.4; 95% CI, −8.09 
to −4.70; P < .0001; 1.25 mg·kg−1: mean difference: −8.8; 95%
CI, −10.89 to −6.72; P < .0001; 2. 5 mg·kg−1: mean difference:
−8.9; 95% CI, −10.75 to −7.05; P < .0001; 5 mg·kg−1: mean dif-
ference: −9.1; 95% CI, −10.8 to −7.4; P < .0001) as analyzed
by 1-way ANOVA (Figure 2A). However, on day 7, animals
administered with the 5 mg·kg−1 dose of dezocine showed
significant reduction in withdrawal signs (mean difference:
Figure 2. Dezocine treatment alleviates morphine withdrawal syndrome with various doses. The morphine withdrawal syndrome decreased 
with the elevation of the dosage of dezocine on day 1 (A) and day 7 (B). Each data point represents mean ± standard error of the mean 
(n = 10). **P < .01 and ‡P < .0001, a significant difference from the dimethyl sulfoxide (DMSO) group in both (A) and (B). #P < .01 and 
##P < .0001, a significant difference from the naive group by 1-way analysis of variance with Tukey’s post hoc test.
−2.3; 95% CI, −3.93 to −0.66; P < .01 by 1-way ANOVA) com-
pared to vehicle-treated controls (Figure 2B). The effect of
0.1–1 mg·kg−1 doses of buprenorphine injections was not
significantly different compared to that in the DMSO group
on day 7 (Figure 2B).
Dezocine Alleviates the Reinstatement of CPP
CPP scores showed no difference in the 4 groups at base-
line. Two-way ANOVA revealed that after receiving mor-
phine injection, CPP scores in the DMSO (mean difference: 
213.6; 95% CI, 97.53–140.9; P < .0001), buprenorphine (mean 
difference: 195.5; 95% CI, 79.38–311.5; P < .001), and dezo-
cine groups (mean difference: 220.3; 95% CI, 104.2–336.4; 
P < .0001) significantly increased with morphine administra-
tion compared to the naive group before drug intervention. 
In the extinction stage, there was no significant difference in 
CPP scores in the 4 groups, which implied that the depen-
dence went away in the DMSO, buprenorphine, and dezo-
cine groups. After reinstatement by morphine (Figure  3), 
CPP scores increased in the DMSO, buprenorphine, and 
dezocine groups. Compared to the DMSO group, scores in 
the dezocine group (mean difference: 314; 95% CI, 197.9–
430.1; P < .0001 by 2-way ANOVA) and the buprenorphine 
control group (mean difference: 261.4; 95% CI, 145.4–377.5; 
P < .0001 2-way ANOVA) markedly decreased. In the rats 
treated with dezocine, there were significant main effects 
of both group and conditioning, F0.05,3,144 = 11.61, P < .0001 
and F0.05,3,144 = 33.59, P < .0001, respectively, as well as sta-
tistically significant group and conditioning interaction, 
F0.05,9,144 = 9.729, P < .0001. No significant difference was 
Figure 3. Dezocine treatment reduced 
reinstatement of morphine-induced 
conditioned place preference (CPP). 
The CPP score was expressed as time 
spent in the drug-associated compart-
ment during a period of 15 min. Results 
are presented as the mean ± standard 
deviation from experiments conducted 
on 10 mice per group. ‡P < .0001 and 
***P < .001, a significant difference 
from the naive group; #P < .0001 a 
significant difference from the dimethyl 
sulfoxide (DMSO) group according to 
2-way analysis of variance (ANOVA) with
Tukey’s post hoc test.
Figure 4. Dezocine inhibits morphine-induced astrocytes activation in nucleus accumbens. A, Immunofluorescence staining for glial fibrillary 
acidic protein (GFAP) in the nucleus accumbens slices of rats in treatment groups. No GFAP overexpression was detected in the naive group. 
However, the number of GFAP-positive cells was significantly increased in the vehicle control group of the morphine-dependent model com-
pared with those in the naive group. GFAP expression was reduced after 3 d of dezocine and buprenorphine administration. B, Summary plot 
of the effect of drugs on fluorescence showing the significant decrease of astrocytes activation in dezocine- and buprenorphine-administered 
animal models compared to the vehicle control. Data represented as the ratio of mean pixel intensity of each group (arbitrary units [AU]) to 
the naive group and shown as mean ± standard error of the mean, n = 6; *P < .05, **P < .01.
observed between the dezocine and buprenorphine groups. 
The data indicated that dezocine significantly alleviated the 
morphine reinstatement effect after dependent effects were 
extinct, suggesting that dezocine could be used for the pre-
vention of opioid relapse.
Dezocine Inhibits Astrocytes Activation in NAcc
Astrocytes of NAcc were a in resting state in animals in the 
naive group (Figure 4A). Immunohistochemistry NAcc sec-
tions showed that chronic morphine administration resulted 
in the activation of astrocytes in a vehicle control group 
characterized by the overexpression of GFAP and enhance-
ment in fluorescence intensity (Figure  4B). Expression of 
GFAP was significantly reduced on the third day of dezo-
cine (mean difference: 4.4; 95% CI, 2.45–6.36; P < .01 by 
1-way ANOVA) and buprenorphine (mean difference: 2.7;
95% CI, 0.34–5.19; P < .05 by 1-way ANOVA) administration 
compared to the DMSO control group (Figure 4B).
Dezocine Inhibits Agonist-Induced Internalization 
of KOR
Whereas dezocine was originally considered as a KOR 
agonist, we20 and others34 recently have shown that dezo-
cine acts as a KOR antagonist. Therefore, it is important to 
determine whether there are similarities between the effects 
of dezocine and other antagonists, such as buprenorphine in 
the agonist-induced KOR trafficking. As shown in Figure 5, 
KOR internalization was induced by 10 µM salvinorin A in 
the Neuro2A cells expressing KOR-tdT fluorescent fusion 
protein. This internalization was blocked by buprenor-
phine pretreatment at concentrations of 0.1, 1, and 10 µM. 
Similarly, pretreatment of cells with 1 or 10 µM dezocine 
blocked the salvinorin A–induced KOR internalization. The 
effect of dezocine was concentration dependent, as at ≤0.1 
µM it did not alter KOR internalization. The result further 
confirmed that dezocine acts as a KOR antagonist, which 
blocks agonist-induced receptor internalization.
Dezocine Has Different Molecular Targets 
Compared to That of Buprenorphine
We have previously demonstrated that dezocine showed 
>50% of the inhibition in μ, κ, and δ opioid receptors with Ki
values of 3.7, 31.9, and 527 nM, respectively.20 Radioligand-
binding assay against tested receptors (Supplemental
Digital Content, Table 1, http://links.lww.com/AA/C329)
revealed the affinity of buprenorphine to μ, κ, and δ recep-
tors with Ki values of 1.0, 0.7, and 1.9 nM, respectively. While 
dezocine interacts with NET (382 nM), SERT (82 nM), and
Figure 5. Dezocine inhibits agonist-induced κ opioid receptor (KOR) internalization. KOR internalization was visualized by fluorescence micros-
copy in control cells either untreated or treated with salvinorin A (A) and in cells pretreated for 30 min with buprenorphine (B) or dezocine (C) 
at indicated doses for 30 min before stimulation with salvinorin A.
sigma-1 (1223 nM) as we reported previously,20 buprenor-
phine has no interaction with these receptors.
DISCUSSION
In this study, we demonstrate that dezocine attenuates the 
symptoms of naloxone-precipitated morphine withdrawal 
syndrome and inhibits associated astrocyte activation in 
NAcc in a morphine-dependent rat model. The decrease in 
the overall withdrawal score produced by dezocine is com-
parable to that by buprenorphine. We also show that dezo-
cine alleviated the reinstatement of morphine-induced CPP 
in rats. This study further confirms that both dezocine and 
buprenorphine are KOR antagonists because both of them 
blocked KOR agonist-induced receptor internalization, the 
process that has been linked to κ agonists–induced behav-
ioral tolerance.10 Microinjections of KOR agonists directly 
into the NAcc demonstrated that KOR activation produces 
stress and depressive-like symptoms such as anhedonia.35 
Prolonged heroin administration significantly increases 
KOR activity in NAcc, which is associated with manifes-
tation of withdrawal-related negative behavioral states in 
drug addiction.36 Consequently, although KOR agonists can 
inhibit the reinforcing effects of abused drugs, by decreas-
ing dopamine concentrations, the use of KOR antagonists 
may be beneficial in treating opioid dependence by sup-
pressing withdrawal symptoms, thereby reducing relapse 
to opioid use, a major symptom of opioid addiction.
Astrocytes of NAcc undergo morphological changes and 
an increase of GFAP expression on exposure to the opioid of 
abuse, that is, activation. Within the NAcc, differently from 
MORs, which are located on the bodies of GABAergic inter-
neurons, KORs are expressed primarily on efferent terminals 
of inputs from the mesolimbic system. Thus, 1 potentially 
important site for the actions of dezocine for morphine with-
drawal is at least, in part, in the NAcc. Given that activation 
of astrocytes in NAcc has been implicated in the develop-
ment of chronic morphine- and cocaine-induced biochemi-
cal and behavioral changes,37 the effectiveness of dezocine 
in inhibiting astrocyte activation in NAcc may indicate its 
clinically relevant efficacy. We previously demonstrated 
that dezocine inhibits norepinephrine and serotonin reup-
take via the interaction with NET and SERT transporters, 
both of which are important targets for neurodegenerative 
diseases, addiction, depression, and pain treatment.20 The 
interaction of dezocine with SERT was also demonstrated in 
a recent in vivo study.38 Competitive binding assay indicated 
that buprenorphine did not interact with these receptors. 
Compared to buprenorphine, dezocine showed the affin-
ity to sigma-1 receptor in addition to the interaction with 
opioid receptors. The interaction of dezocine with sigma-1 
receptor might contribute to its nonaddictive or antidepen-
dence property. It is unclear whether dezocine can activate 
or inhibit this receptor. Various studies have suggested that 
sigma-1 receptor activation plays a critical role in plasticity 
related to reinforcement and addiction processes. Sigma-1 
receptor as a receptor chaperone modulates the activities of 
G-protein–coupled receptors, ion channels, and signaling 
molecules under pathophysiological conditions, includ-
ing addiction, pain, and depression.39 The sigma-1 recep-
tor gene and protein expression were upregulated in brain 
regions related to addiction and reward. CPP induced by
cocaine can be blocked by a sigma-1 receptor antagonism, 
suggesting that targeting sigma-1 receptors might provide a 
potential approach in managing addition.40 Taken together, 
the findings from this study suggest that the interaction 
of dezocine with KOR, NET, SERT, and sigma-1 proteins 
could be the possible mechanisms that underlie its nonad-
dictive property and the antiwithdrawal effects of dezocine 
and provides potential strategies for opioid dependence 
research and therapy. However, more studies are needed to 
investigate the intracellular events occurring after dezocine 
administration and to reveal pharmacological significance 
of aforementioned targets in the reward pathways at the 
molecular level.
In summary, we demonstrated that dezocine, a nonad-
dictive opioid, significantly reduced opioid withdrawal 
syndrome in a morphine-dependent rat model comparable 
to that of buprenorphine, indicating that dezocine could be 
a potential alternative medication for the management of 
withdrawal syndrome in opioid dependence. The similarity 
of dezocine and buprenorphine as opioids is partial MOR 
agonism and KOR antagonism. Both of them can inhibit 
NAcc astrocytes activation. The differences in molecular 
targets between buprenorphine and dezocine clearly indi-
cate that dezocine might have important value in study-
ing the mechanisms of opioid dependence and developing 
novel therapeutics. 
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